Oct 15 (Reuters) - Transition Therapeutics Inc TTH.TO :
* Announces results of data analysis from ELND005 phase 2/3 clinical study in
agitation and aggression in alzheimer's disease patients
* Says ELND005 demonstrated acceptable safety and tolerability profile
* To meet with regulators to seek guidance on ELND005 phase 3 program for ad
patients with severe agitation and aggression
* ELND005 demonstrated numerical improvement in 20 of 21 symptoms measured as
part of primary efficacy endpoint
* Over the next few months, TTIL intends to submit a request to the FDA to discuss the data from the completed phase 2/3 study
* Source text for Eikon ID:nPnchlTY
* Further company coverage TTH.TO